[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2009003676A - Compuestos s-nitrosotiol y derivados relacionados. - Google Patents

Compuestos s-nitrosotiol y derivados relacionados.

Info

Publication number
MX2009003676A
MX2009003676A MX2009003676A MX2009003676A MX2009003676A MX 2009003676 A MX2009003676 A MX 2009003676A MX 2009003676 A MX2009003676 A MX 2009003676A MX 2009003676 A MX2009003676 A MX 2009003676A MX 2009003676 A MX2009003676 A MX 2009003676A
Authority
MX
Mexico
Prior art keywords
breathing
directed
lack
treating
related derivatives
Prior art date
Application number
MX2009003676A
Other languages
English (en)
Inventor
James C Mannion
Original Assignee
Galleon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galleon Pharmaceuticals Inc filed Critical Galleon Pharmaceuticals Inc
Publication of MX2009003676A publication Critical patent/MX2009003676A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un método para el tratamiento de una falta de control de respiración normal incluyendo el tratamiento de apnea e hipoventilación asociados con sueño, obesidad, ciertas medicinas y otras condiciones médicas; en un aspecto, la invención se refiere al tratamiento del control trastornado de la respiración al administrar una composición que comprende un compuesto sencillo que trata la falta de la respiración normal; en otro aspecto, la invención se refiere al tratamiento del control trastornado de la respiración al administrar una composición que comprende una combinación de dos o más compuestos, al menos uno de los cuales trata la falta de la respiración normal; en un aspecto, un compuesto es un agente de S-nitrosilación.
MX2009003676A 2006-10-03 2007-10-03 Compuestos s-nitrosotiol y derivados relacionados. MX2009003676A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84926306P 2006-10-03 2006-10-03
PCT/US2007/021311 WO2008066603A2 (en) 2006-10-03 2007-10-03 S-nitrosothiol compounds and related derivatives

Publications (1)

Publication Number Publication Date
MX2009003676A true MX2009003676A (es) 2009-07-16

Family

ID=39468412

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003676A MX2009003676A (es) 2006-10-03 2007-10-03 Compuestos s-nitrosotiol y derivados relacionados.

Country Status (10)

Country Link
US (1) US20100105685A1 (es)
EP (1) EP2068903A4 (es)
JP (1) JP2010505844A (es)
KR (1) KR20090083891A (es)
CN (1) CN101547703A (es)
AU (1) AU2007325972A1 (es)
BR (1) BRPI0718199A2 (es)
CA (1) CA2665210A1 (es)
MX (1) MX2009003676A (es)
WO (1) WO2008066603A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101073A1 (en) * 2010-10-22 2012-04-26 Galleon Pharmaceutical, Inc. Novel Method For Treating Breathing Disorders or Diseases
WO2012166909A1 (en) * 2011-06-03 2012-12-06 Galleon Pharmaceuticals, Inc. Compositions and methods for treating breathing control disorders or diseases
LT3066089T (lt) * 2013-11-08 2020-02-25 Promentis Pharmaceuticals, Inc. Pakeistieji n-acetil-l-cisteino dariniai ir giminingi junginiai
KR102704068B1 (ko) * 2019-06-17 2024-09-06 주식회사 차메디텍 Sac 유도체 또는 smc 유도체를 포함하는 피부 각질형성세포 분화 촉진용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3343141A1 (de) * 1983-11-29 1985-06-05 Hermann P.T. 7400 Tübingen Ammon Verwendung von cystein-derivaten oder deren salzen, zur steigerung der insulinsekretion der langerhans'schen inseln der bauchspeicheldruese
IL98310A (en) * 1990-06-08 1996-08-04 Astra Ab Medicinal preparations containing a history of cystine
US5380758A (en) * 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
ZA963590B (en) * 1995-05-10 1996-11-19 Adcock Ingram Ltd Pharmaceutical composition
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
WO2003002125A2 (en) * 2001-06-29 2003-01-09 Astion A/S Combination of aminosugars and cysteine or cysteine derivatives
CA2459647A1 (en) * 2001-08-20 2003-02-27 University Of Virginia Patent Foundation Use of s-nitrosothiol signaling to treat disordered control of breathing
NZ545132A (en) * 2003-07-08 2009-07-31 Astrazeneca Ab Spiro[1-azabicyclo[2.2.2.]octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders

Also Published As

Publication number Publication date
WO2008066603A3 (en) 2008-10-02
JP2010505844A (ja) 2010-02-25
WO2008066603A2 (en) 2008-06-05
BRPI0718199A2 (pt) 2013-11-12
CA2665210A1 (en) 2008-06-05
CN101547703A (zh) 2009-09-30
AU2007325972A1 (en) 2008-06-05
KR20090083891A (ko) 2009-08-04
EP2068903A4 (en) 2010-11-03
US20100105685A1 (en) 2010-04-29
EP2068903A2 (en) 2009-06-17

Similar Documents

Publication Publication Date Title
MX2010004450A (es) Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
MX2010002498A (es) Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.
HK1129594A1 (en) Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain
WO2006023702A3 (en) Method for treating sleep related breathing disorders with setiptiline
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
MY160894A (en) Oligosaccharide composition for treating skin diseases
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
MY188457A (en) Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
TN2011000176A1 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
WO2009037583A3 (en) Compositions and methods for treatment and prevention of osteoarthritis
MX2007003157A (es) 4-feniltetrahidroisoquinolinas sustituidas, metodo para su produccion, su uso como medicamento y un medicamento que las contiene.
MX2009011900A (es) Curacion de herida diabetica.
MY139498A (en) Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines
WO2007035879A3 (en) Combination s-nitrosothiol-based pharmaceutical products for restoring normal breathing rhythm
TNSN08506A1 (en) Substituted carboxamides
MX2009003676A (es) Compuestos s-nitrosotiol y derivados relacionados.
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
MX2008011020A (es) Compuestos de receptor sigma.
EP2801359A3 (en) The use of nicotine for the treatment of sepsis in humans caused by antibiotic
BRPI0509210A (pt) uso de gaboxadol, e, métodos para tratar função respiratória enfraquecida, e apnéia do sono
MX2009001433A (es) Nucleosidos para suprimir o reducir el desarrollo de resistencia en terapia citostatica.
UA99638C2 (ru) Оксазолидиноны для лечения и/или профилактики сердечной недостаточности
MX2009005912A (es) Derivados de etilamina-fenilo heterociclilo sustituidos, su preparacion y uso como medicamentos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal